Literature DB >> 28420704

Influence of HDL particles on cell-cholesterol efflux under various pathological conditions.

Bela F Asztalos1,2, Katalin V Horvath3,2, Michael Mehan2, Yuya Yokota3, Ernst J Schaefer3,2.   

Abstract

It has been reported that low cell-cholesterol efflux capacity (CEC) of HDL is an independent risk factor for CVD. To better understand CEC regulation, we measured ABCA1- and scavenger receptor class B type I (SR-BI)-dependent cell-cholesterol efflux, HDL anti-oxidative capacity, HDL particles, lipids, and inflammatory- and oxidative-stress markers in 122 subjects with elevated plasma levels of triglyceride (TG), serum amyloid A (SAA), fibrinogen, myeloperoxidase (MPO), or β-sitosterol and in 146 controls. In controls, there were strong positive correlations between ABCA1-dependent cholesterol efflux and small preβ-1 concentrations (R2 = 0.317) and SR-BI-dependent cholesterol efflux and large (α-1 + α-2) HDL particle concentrations (R2 = 0.774). In high-TG patients, both the concentration and the functionality (preβ-1 concentration-normalized ABCA1 efflux) of preβ-1 particles were significantly elevated compared with controls; however, though the concentration of large particles was significantly decreased, their functionality (large HDL concentration-normalized SR-BI efflux) was significantly elevated. High levels of SAA or MPO were not associated with decreased functionality of either the small (preβ-1) or the large (α-1 + α-2) HDL particles. HDL anti-oxidative capacity was negatively influenced by high plasma β-sitosterol levels, but not by the concentrations of HDL particles, TG, SAA, fibrinogen, or MPO. Our data demonstrate that under certain conditions CEC is influenced not only by quantitative (concentration), but also by qualitative (functional) properties of HDL particles.
Copyright © 2017 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  adenosine triphosphate binding cassette transporter A1; apolipoprotein A-I; cardiovascular disease risk; preβ-1; scavenger receptor class B type I

Mesh:

Substances:

Year:  2017        PMID: 28420704      PMCID: PMC5454514          DOI: 10.1194/jlr.M075648

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  32 in total

Review 1.  Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges.

Authors:  Robert S Rosenson; H Bryan Brewer; Benjamin Ansell; Philip Barter; M John Chapman; Jay W Heinecke; Anatol Kontush; Alan R Tall; Nancy R Webb
Journal:  Circulation       Date:  2013-09-10       Impact factor: 29.690

2.  Relation of increased prebeta-1 high-density lipoprotein levels to risk of coronary heart disease.

Authors:  Lin T Guey; Clive R Pullinger; Brian Y Ishida; Patricia M O'Connor; Christian Zellner; Omar L Francone; Jason M Laramie; Josefina M Naya-Vigne; Ketevan A Siradze; Prakash Deedwania; Rita F Redberg; Philip H Frost; Albert B Seymour; John P Kane; Mary J Malloy
Journal:  Am J Cardiol       Date:  2011-08-01       Impact factor: 2.778

3.  Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions.

Authors:  Baohai Shao; Subramaniam Pennathur; Jay W Heinecke
Journal:  J Biol Chem       Date:  2012-01-04       Impact factor: 5.157

4.  Pre beta 1-high-density lipoprotein increases in coronary artery disease.

Authors:  T Miida; Y Nakamura; K Inano; T Matsuto; T Yamaguchi; T Tsuda; M Okada
Journal:  Clin Chem       Date:  1996-12       Impact factor: 8.327

5.  Carotid intima media thickness is related positively to plasma pre ß-high density lipoproteins in non-diabetic subjects.

Authors:  Rindert de Vries; Frank G Perton; Arie van Tol; Robin P F Dullaart
Journal:  Clin Chim Acta       Date:  2011-11-11       Impact factor: 3.786

6.  Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.

Authors:  William E Boden; Jeffrey L Probstfield; Todd Anderson; Bernard R Chaitman; Patrice Desvignes-Nickens; Kent Koprowicz; Ruth McBride; Koon Teo; William Weintraub
Journal:  N Engl J Med       Date:  2011-11-15       Impact factor: 91.245

7.  Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy.

Authors:  C M Ballantyne; J A Herd; L L Ferlic; J K Dunn; J A Farmer; P H Jones; J R Schein; A M Gotto
Journal:  Circulation       Date:  1999-02-16       Impact factor: 29.690

8.  Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional.

Authors:  Joseph A DiDonato; Kulwant Aulak; Ying Huang; Matthew Wagner; Gary Gerstenecker; Celalettin Topbas; Valentin Gogonea; Anthony J DiDonato; W H Wilson Tang; Ryan A Mehl; Paul L Fox; Edward F Plow; Jonathan D Smith; Edward A Fisher; Stanley L Hazen
Journal:  J Biol Chem       Date:  2014-02-20       Impact factor: 5.157

9.  Impact of simvastatin, niacin, and/or antioxidants on cholesterol metabolism in CAD patients with low HDL.

Authors:  Nirupa R Matthan; Ann Giovanni; Ernst J Schaefer; B Greg Brown; Alice H Lichtenstein
Journal:  J Lipid Res       Date:  2003-02-01       Impact factor: 5.922

Review 10.  Myeloperoxidase: an oxidative pathway for generating dysfunctional high-density lipoprotein.

Authors:  Baohai Shao; Michael N Oda; John F Oram; Jay W Heinecke
Journal:  Chem Res Toxicol       Date:  2010-03-15       Impact factor: 3.739

View more
  14 in total

Review 1.  Time to ditch HDL-C as a measure of HDL function?

Authors:  Graziella E Ronsein; Jay W Heinecke
Journal:  Curr Opin Lipidol       Date:  2017-10       Impact factor: 4.776

2.  The lipid transfer properties of CETP define the concentration and composition of plasma lipoproteins.

Authors:  Richard E Morton; Yan Liu
Journal:  J Lipid Res       Date:  2020-06-26       Impact factor: 5.922

3.  Sex steroids mediate discrete effects on HDL cholesterol efflux capacity and particle concentration in healthy men.

Authors:  Katya B Rubinow; Tomas Vaisar; Jing H Chao; Jay W Heinecke; Stephanie T Page
Journal:  J Clin Lipidol       Date:  2018-04-30       Impact factor: 4.766

4.  ABCA1, ABCG1, and Cholesterol Homeostasis.

Authors:  Xiao-Hua Yu; Chao-Ke Tang
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  High-Density Lipoprotein Particles, Cell-Cholesterol Efflux, and Coronary Heart Disease Risk.

Authors:  Bela F Asztalos; Katalin V Horvath; Ernst J Schaefer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-09       Impact factor: 8.311

6.  Genetic and secondary causes of severe HDL deficiency and cardiovascular disease.

Authors:  Andrew S Geller; Eliana Y Polisecki; Margaret R Diffenderfer; Bela F Asztalos; Sotirios K Karathanasis; Robert A Hegele; Ernst J Schaefer
Journal:  J Lipid Res       Date:  2018-10-17       Impact factor: 5.922

7.  Perimenopausal transdermal estradiol replacement reduces serum HDL cholesterol efflux capacity but improves cardiovascular risk factors.

Authors:  Tomas Vaisar; Jennifer L Gordon; Jake Wimberger; Jay W Heinecke; Alan L Hinderliter; David R Rubinow; Susan S Girdler; Katya B Rubinow
Journal:  J Clin Lipidol       Date:  2020-11-24       Impact factor: 4.766

8.  Cardiovascular Risk Factor Reduction in First Responders Resulting From an Individualized Lifestyle and Blood Test Program: A Randomized Controlled Trial.

Authors:  Rosalynn Gill; Harold Robert Superko; Megan M McCarthy; Kepra Jack; Briana Jones; Debanjali Ghosh; Steve Richards; Joi A Gleason; Paul T Williams; Michael Dansinger
Journal:  J Occup Environ Med       Date:  2019-03       Impact factor: 2.162

Review 9.  Advances in HDL: Much More than Lipid Transporters.

Authors:  Soumaya Ben-Aicha; Lina Badimon; Gemma Vilahur
Journal:  Int J Mol Sci       Date:  2020-01-22       Impact factor: 5.923

10.  Anti-Inflammatory HDL Function, Incident Cardiovascular Events, and Mortality: A Secondary Analysis of the JUPITER Randomized Clinical Trial.

Authors:  Oluremi N Ajala; Olga V Demler; Yanyan Liu; Zareen Farukhi; Steven J Adelman; Heidi L Collins; Paul M Ridker; Daniel J Rader; Robert J Glynn; Samia Mora
Journal:  J Am Heart Assoc       Date:  2020-08-15       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.